Protalix Biotherapeutics Stock Analysis

Protalix Stock Analysis Notes

About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.15. Protalix Biotherapeutics last dividend was issued on the 20th of December 2019. The entity had 1:10 split on the 20th of December 2019. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people. To find out more about Protalix Biotherapeutics contact Dror Bashan at 972 4 902 8100 or learn more at https://www.protalix.com.

Protalix Biotherapeutics Investment Alerts

Protalix Biotherapeutics Upcoming and Recent Events

Protalix Largest EPS Surprises

View All Earnings Estimates

Protalix Biotherapeutics Environmental, Social, and Governance (ESG) Scores

Protalix Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 175.25 M.

Protalix Profitablity

The company has Net Profit Margin of (0.39) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.18) %, which entails that for every $100 of revenue, it lost $0.18.

Management Efficiency

Protalix Biotherapeutics has Return on Asset of (0.1027) % which means that on every $100 spent on assets, it lost $0.1027. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4349) %, meaning that it generated no profit with money invested by stockholders. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.32 in 2025, whereas Return On Equity is likely to drop 0.21 in 2025. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.12 in 2025, whereas Total Assets are likely to drop slightly above 51 M in 2025.

Technical Drivers

As of the 31st of January, Protalix Biotherapeutics holds the Coefficient Of Variation of 313.24, risk adjusted performance of 0.2747, and Semi Deviation of 2.35. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them.

Protalix Biotherapeutics Price Movement Analysis

Protalix Biotherapeutics Insider Trading Activities

Protalix Biotherapeutics Outstanding Bonds

Protalix Biotherapeutics Predictive Daily Indicators

Protalix Biotherapeutics Corporate Filings

Protalix Biotherapeutics Forecast Models

Protalix Biotherapeutics' time-series forecasting models are one of many Protalix Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protalix Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Protalix Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Protalix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Protalix Biotherapeutics. By using and applying Protalix Stock analysis, traders can create a robust methodology for identifying Protalix entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Protalix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Protalix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Protalix Biotherapeutics stock analysis indicators help investors evaluate how Protalix Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Protalix Biotherapeutics shares will generate the highest return on investment. By understating and applying Protalix Biotherapeutics stock analysis, traders can identify Protalix Biotherapeutics position entry and exit signals to maximize returns.

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.